• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 与长期预后:其他重症疾病的经验教训及潜在机制

COVID-19 and Long-Term Outcomes: Lessons from Other Critical Care Illnesses and Potential Mechanisms.

机构信息

Morehouse School of Medicine, Atlanta, Georgia.

Department of Biomedical Sciences.

出版信息

Am J Respir Cell Mol Biol. 2022 Sep;67(3):275-283. doi: 10.1165/rcmb.2021-0374PS.

DOI:10.1165/rcmb.2021-0374PS
PMID:35348443
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9447134/
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that is currently causing a pandemic and has been termed coronavirus disease (COVID-19). The elderly or those with preexisting conditions like diabetes, hypertension, coronary heart disease, chronic obstructive pulmonary disease, cerebrovascular disease, or kidney dysfunction are more likely to develop severe cases when infected. Patients with COVID-19 admitted to the ICU have higher mortality than non-ICU patients. Critical illness has consistently posed a challenge not only in terms of mortality but also in regard to long-term outcomes of survivors. Patients who survive acute critical illness including, but not limited to, pulmonary and systemic insults associated with acute respiratory distress syndrome, pneumonia, systemic inflammation, and mechanical ventilation, will likely suffer from post-ICU syndrome, a phenomenon of cognitive, psychiatric, and/or physical disability after treatment in the ICU. Post-ICU morbidity and mortality continue to be a cause for concern when considering large-scale studies showing 12-month mortality risks of 11.8-21%. Previous studies have demonstrated that multiple mechanisms, including cytokine release, mitochondrial dysfunction, and even amyloids, may lead to end-organ dysfunction in patients. We hypothesize that COVID-19 infection will lead to post-ICU syndrome via potentially similar mechanisms as other chronic critical illnesses and cause long-term morbidity and mortality in patients. We consider a variety of mechanisms and questions that not only consider the short-term impact of the COVID-19 pandemic but its long-term effects that may not yet be imagined.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)是一种新型冠状病毒,目前正在引发大流行,并被称为冠状病毒病(COVID-19)。老年人或患有糖尿病、高血压、冠心病、慢性阻塞性肺疾病、脑血管病或肾功能不全等既往疾病的人在感染后更有可能出现严重病例。入住 ICU 的 COVID-19 患者的死亡率高于非 ICU 患者。危重病不仅在死亡率方面,而且在幸存者的长期预后方面一直是一个挑战。包括但不限于与急性呼吸窘迫综合征、肺炎、全身炎症和机械通气相关的肺和全身损伤在内的急性危重病患者可能会患有 ICU 后综合征,这是一种 ICU 治疗后认知、精神和/或身体残疾的现象。在考虑大规模研究时,ICU 后发病率和死亡率仍然令人担忧,这些研究显示 12 个月的死亡率风险为 11.8-21%。先前的研究表明,多种机制,包括细胞因子释放、线粒体功能障碍,甚至淀粉样物质,可能导致患者的终末器官功能障碍。我们假设 COVID-19 感染将通过与其他慢性危重病相似的潜在机制导致 ICU 后综合征,并在患者中造成长期发病率和死亡率。我们考虑了多种机制和问题,这些机制和问题不仅考虑了 COVID-19 大流行的短期影响,还考虑了可能尚未想象到的长期影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cead/9447134/ff7957c325f9/rcmb.2021-0374PSf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cead/9447134/5769a78603c3/rcmb.2021-0374PSf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cead/9447134/ff7957c325f9/rcmb.2021-0374PSf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cead/9447134/5769a78603c3/rcmb.2021-0374PSf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cead/9447134/ff7957c325f9/rcmb.2021-0374PSf2.jpg

相似文献

1
COVID-19 and Long-Term Outcomes: Lessons from Other Critical Care Illnesses and Potential Mechanisms.COVID-19 与长期预后:其他重症疾病的经验教训及潜在机制
Am J Respir Cell Mol Biol. 2022 Sep;67(3):275-283. doi: 10.1165/rcmb.2021-0374PS.
2
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
3
Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy.重症监护治疗新型冠状病毒 SARS-CoV-2 感染患者:意大利克雷马医院的经验。
Am J Emerg Med. 2021 Jul;45:156-161. doi: 10.1016/j.ajem.2020.08.005. Epub 2020 Aug 16.
4
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.意大利伦巴第地区 1591 名 ICU 收治的 SARS-CoV-2 感染患者的基线特征和结局。
JAMA. 2020 Apr 28;323(16):1574-1581. doi: 10.1001/jama.2020.5394.
5
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局:一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
6
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.新冠康复者血浆或超免疫球蛋白用于新冠患者:快速综述
Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600.
7
Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial.多中心、三臂、随机对照试验研究甲泼尼龙和普通肝素在 SARS-CoV-2 感染肺炎危重症机械通气患者中的应用:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Aug 17;21(1):724. doi: 10.1186/s13063-020-04645-z.
8
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.扩充脐带间充质干细胞(UC-MSCs)作为治疗危重症 COVID-19 患者的一种治疗策略:同情用药的理由。
Pain Physician. 2020 Mar;23(2):E71-E83.
9
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
10
Care bundles for improving outcomes in patients with COVID-19 or related conditions in intensive care - a rapid scoping review.改善重症监护病房中新冠肺炎患者或相关病症患者预后的综合照护措施——一项快速综述
Cochrane Database Syst Rev. 2020 Dec 21;12(12):CD013819. doi: 10.1002/14651858.CD013819.

引用本文的文献

1
Relationship of right ventricular functions with in-hospital and 1 year later mortality in patients hospitalized for COVID-19 pneumonia.新型冠状病毒肺炎住院患者右心室功能与住院期间及1年后死亡率的关系。
Ann Thorac Med. 2024 Jan-Mar;19(1):96-104. doi: 10.4103/atm.atm_172_23. Epub 2024 Jan 25.
2
Tau and Aβ42 in lavage fluid of pneumonia patients are associated with end-organ dysfunction: A prospective exploratory study.肺炎患者灌洗液中的 Tau 和 Aβ42 与终末器官功能障碍相关:一项前瞻性探索性研究。
PLoS One. 2024 Feb 23;19(2):e0298816. doi: 10.1371/journal.pone.0298816. eCollection 2024.
3
Development and validation of a prognostic model based on clinical laboratory biomarkers to predict admission to ICU in Omicron variant-infected hospitalized patients complicated with myocardial injury.

本文引用的文献

1
Lung Function and Symptoms in Post-COVID-19 Patients: A Single-Center Experience.新冠康复患者的肺功能与症状:单中心经验
Mayo Clin Proc Innov Qual Outcomes. 2021 Oct;5(5):907-915. doi: 10.1016/j.mayocpiqo.2021.08.002. Epub 2021 Aug 10.
2
Cellular and Exosomal Regulations of Sepsis-Induced Metabolic Alterations.细胞和细胞外囊泡对脓毒症引起的代谢改变的调控。
Int J Mol Sci. 2021 Aug 2;22(15):8295. doi: 10.3390/ijms22158295.
3
Amyloid Prefibrillar Oligomers: The Surprising Commonalities in Their Structure and Activity.淀粉样原纤维寡聚物:它们在结构和活性方面的惊人共性。
基于临床实验室生物标志物的预测奥密克戎变异株感染住院合并心肌损伤患者入住 ICU 的预后模型的建立与验证。
Front Immunol. 2024 Feb 1;15:1268213. doi: 10.3389/fimmu.2024.1268213. eCollection 2024.
4
Lung endothelium, tau, and amyloids in health and disease.肺内皮细胞、tau 蛋白和淀粉样物质在健康与疾病中的作用。
Physiol Rev. 2024 Apr 1;104(2):533-587. doi: 10.1152/physrev.00006.2023. Epub 2023 Aug 10.
5
Common molecular signatures between coronavirus infection and Alzheimer's disease reveal targets for drug development.冠状病毒感染与阿尔茨海默病之间的共同分子特征揭示了药物开发的靶点。
bioRxiv. 2023 Jun 15:2023.06.14.544970. doi: 10.1101/2023.06.14.544970.
6
Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study.瑞德西韦与新冠重症患者的生存结局:一项多中心观察性队列研究
J Infect. 2023 Mar;86(3):256-308. doi: 10.1016/j.jinf.2022.12.027. Epub 2022 Dec 31.
7
Resurrecting Epstein-Barr Virus.复活爱泼斯坦-巴尔病毒。
Pathogens. 2022 Jul 6;11(7):772. doi: 10.3390/pathogens11070772.
8
New Insights into Clinical and Mechanistic Heterogeneity of the Acute Respiratory Distress Syndrome: Summary of the Aspen Lung Conference 2021.急性呼吸窘迫综合征的临床和机制异质性的新见解:2021 年阿斯彭肺会议总结。
Am J Respir Cell Mol Biol. 2022 Sep;67(3):284-308. doi: 10.1165/rcmb.2022-0089WS.
Int J Mol Sci. 2021 Jun 16;22(12):6435. doi: 10.3390/ijms22126435.
4
Long-term consequences in critically ill COVID-19 patients: A prospective cohort study.危重症 COVID-19 患者的长期后果:一项前瞻性队列研究。
Acta Anaesthesiol Scand. 2021 Oct;65(9):1285-1292. doi: 10.1111/aas.13939. Epub 2021 Jun 25.
5
3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study.COVID-19 相关住院患者的 3 个月、6 个月、9 个月和 12 个月呼吸结局:一项前瞻性研究。
Lancet Respir Med. 2021 Jul;9(7):747-754. doi: 10.1016/S2213-2600(21)00174-0. Epub 2021 May 5.
6
SARS-CoV-2 (COVID-19) and the Endocrine System.严重急性呼吸综合征冠状病毒2(新冠病毒)与内分泌系统
J Endocr Soc. 2020 Oct 1;4(11):bvaa144. doi: 10.1210/jendso/bvaa144. eCollection 2020 Nov 1.
7
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.严重和危重新冠肺炎中的细胞因子升高:快速系统评价、荟萃分析,并与其他炎症综合征比较。
Lancet Respir Med. 2020 Dec;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5. Epub 2020 Oct 16.
8
Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection.血管紧张素转换酶 2 和周细胞在 COVID-19 感染心脏并发症中的作用。
Am J Physiol Heart Circ Physiol. 2020 Nov 1;319(5):H1059-H1068. doi: 10.1152/ajpheart.00681.2020. Epub 2020 Oct 9.
9
As Their Numbers Grow, COVID-19 "Long Haulers" Stump Experts.随着新冠“长期症状者”数量的增加,专家们也感到困惑。
JAMA. 2020 Oct 13;324(14):1381-1383. doi: 10.1001/jama.2020.17709.
10
COVID-19 and Respiratory System Disorders: Current Knowledge, Future Clinical and Translational Research Questions.新型冠状病毒肺炎与呼吸系统疾病:现有知识及未来临床与转化研究问题
Arterioscler Thromb Vasc Biol. 2020 Nov;40(11):2586-2597. doi: 10.1161/ATVBAHA.120.314515. Epub 2020 Sep 22.